

## **Round Table Discussion:**

### ***Epigenetics, the Road Ahead: Are Polypharmacology and Epitranscriptomics our Bright Future?***

#### **Panelist:**

Dr Haiching Ma (Reaction Biology, United States)

Dr. Ma joined Reaction Biology in 2001 as employee number one. He is the Chief Science Officer, where he developed and implemented the current Reaction Biology technology and service platforms. Dr. Ma is the Principal Investigator for multiple SBIR awards and an RO1 award from NIH all Reaction Biology totaling over \$12 million, and which cover research topics including assay development for human kinome and epigenome targets, toxicity predictions, chemical microarray HTS and cell death prevention that reduce side effects from radiation therapies. Dr. Ma is serving as a national Steering Committee Member for the NIH National Cancer Institute's Chemical Biology Consortium. He received his Ph.D. in Pharmacology from the Medical School of The University of Pennsylvania and continued his postdoc training there in the Institute for Medicine and Engineering.